A research-use platform that returns a per-gene mutation prediction from a scanned blood or bone marrow smear, with calibrated confidence and explicit abstention, bound to a signed and publicly anchored record. It runs in the cloud or fully air-gapped on the machine holding the slide.
Rank which trial candidates to sequence first for a target mutation, so a sponsor fills a marker-defined cohort with fewer assays and a signed record of every selection. It ranks, it never decides. Sequencing always confirms enrollment, and a recall floor bounds what the ranking can miss.
Candidates are ordered by morphology-predicted likelihood of the trial's target marker. Known molecular status is used only as retrospective ground truth to score a ranking, never as an input to it.
Research use onlyThe report names the smallest sequencing depth that still captures the stated fraction of marker-positive patients on that cohort, so what the ranking can miss is a published number rather than a hope.
Signed · verifiableAxiisium is Research Use Only. Replacing any assay in clinical practice is earned through the De Novo pathway and prospective trials, one gene at a time, and nothing on this site claims otherwise. Until then the product routes sequencing; it does not stand in for it.
Design partners: labs, sponsors and pediatric centers with archived diagnostic smears and the molecular results already on file. No new patient, no new needle, and it is how the external validation gets built.